Guardant Health (NASDAQ:GH) Issues Quarterly Earnings Results

Guardant Health (NASDAQ:GH) released its quarterly earnings data on Thursday. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.15), Zacks reports. Guardant Health had a negative return on equity of 1,200.44% and a negative net margin of 74.02%. Guardant Health updated its FY 2025 guidance to EPS.

Guardant Health Price Performance

GH traded down $1.60 during trading on Thursday, hitting $47.40. The company had a trading volume of 3,021,831 shares, compared to its average volume of 2,470,453. Guardant Health has a 1-year low of $15.81 and a 1-year high of $50.89. The company has a market cap of $5.86 billion, a PE ratio of -11.18 and a beta of 1.32. The business has a 50-day moving average of $39.78 and a 200-day moving average of $31.39.

Insiders Place Their Bets

In related news, Director Musa Tariq sold 2,320 shares of the business’s stock in a transaction dated Friday, December 13th. The stock was sold at an average price of $35.00, for a total value of $81,200.00. Following the completion of the sale, the director now directly owns 2,676 shares of the company’s stock, valued at $93,660. The trade was a 46.44 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders sold a total of 2,652 shares of company stock valued at $93,192 in the last ninety days. Corporate insiders own 5.50% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on GH shares. JPMorgan Chase & Co. increased their target price on shares of Guardant Health from $48.00 to $50.00 and gave the stock an “overweight” rating in a research report on Thursday, November 7th. Sanford C. Bernstein dropped their price objective on shares of Guardant Health from $40.00 to $35.00 and set an “outperform” rating for the company in a research report on Wednesday, October 30th. Barclays initiated coverage on shares of Guardant Health in a report on Thursday, January 23rd. They set an “overweight” rating and a $60.00 target price on the stock. The Goldman Sachs Group increased their price target on Guardant Health from $36.00 to $49.00 and gave the company a “buy” rating in a report on Tuesday, January 28th. Finally, Guggenheim restated a “buy” rating on shares of Guardant Health in a research note on Wednesday, January 22nd. Sixteen research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Guardant Health has an average rating of “Buy” and an average price target of $42.63.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.